Skip to main content

Advertisement

Table 1 Differences and comparison between mucinous and non-mucinous patients with colorectal cancer in 14 clinical trials

From: Mucinous colorectal adenocarcinoma: clinical pathology and treatment options

Clinical trial Type of hemotherapy Stage Chemotherapy regimen Patients (n, MC/NMC) Median OS (months) OS rate (%) HR
MC NMC MC NMC
Tumor location: colorectal
Negri 2005 [63] Palliative IV 5-FU based first-line chemotherapy 135 (45/90) 11.8 17.9 1.50
Catalano 2009 [8] Palliative IV 5-FU with OXA and/or CPT-11 based first-line combination chemotherapy 255 (49/206) 14.0 23.4 53.1% (1-year) 77.4% (1-year) 1.59
Mekenkamp Study 1 2012 [64] Palliative IV First-line sequential or combination treatment with CAP, CPT-11 and OXA. 485 (50/435) 13.2 19.2 1.80
Mekenkamp Study 2 2012 [64] Palliative IV CAP, OXA and BEV with or without CET 525 (49/476) 13.1 21.5 1.76
Park 2015 [65] Adjuvant I–III 5-FU based chemotherapy 6475 (274/6201) 81.4% (5-year) 87.4% (5-year) 1.58
Tumor location: colon
Maisano 2012 [60] Palliative IV FOLFOX-4 regimen [OXA, LV, 5-FU] 63 (21/42) 8.0 18.0 1.99
Catalano 2012 [23] Adjuvant II–III Fluoropyrimidine-based or OXA-based chemotherapy 1025 78.6% (5-year) 72.3% (5-year) 0.89
Kim 2013 [14] Adjuvant chemotherapy III FOLFOX chemotherapy [LV, 5-FU, OXA] 394 56.9% (3-year DFS) 79.2% (3-year DFS) 1.82
Tumor location: rectal
Sengul 2006 [66] PCRT III–IV 45–60 Gy and an infusion of 5-FU 46 (11/35)
Grillo-Ruggieri 2007 [98] PCRT II–IV 50.4 Gy and 5-FU-based chemotherapy 136 (25/111) 89.0% (5-year) 83.9% (5-year) 0.35
Shin 2011 [99] PCRT III–IV 45–50.4 Gy and 5-FU- or CAP-based chemotherapy 368 (23/345) 64.8% (5-year) 79.8% (5-year) 2.36
Simha 2014 [67] PCRT I–IV 45 Gy and 5-FU and LV 162 (34,128)
Hugen 2015 [69] PCRT II–III 45–50.4 Gy and CAP with or without OXA/BEV or 5-FU 540 (58/482) 53.1% (5-year) 54.1% (5-year)
Hugen 2013 [9] Adjuvant I–IV 5-FU or CAP with or without OXA 9045 (744/8301) 41.0% (5-year) 51.2% (5-year) 1.22
  1. MC mucinous colorectal adenocarcinoma, NMC non-mucinous colorectal adenocarcinoma, PRCT preoperative chemoradiotherapy, OS overall survival, HR hazard ratio, 5-FU 5-fluorouracil, OXA oxaliplatin, CAP capecitabine, BEV bevacizumab, CET cetuximab, LV leucovorin, CPT-11 irinotecan